Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

nal Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's RSV vaccine program.  This grant will be used to further advance the novel pediatric RSV vaccine.
 
  • Promising data were presented on GenVec's RSV vaccine program at the 8th Annual International Respiratory Syncytial Virus Symposium, demonstrating that GenVec's pre-clinical, universal RSV vaccine candidate is highly immunogenic and produces durable and broad protection from a single intramuscular administration.  Protection in cotton rat and mouse models was characterized by functional RSV neutralizing antibodies and no disease potentiation was observed.
     
  • Encouraging preclinical proof of concept data generated in non-human primates involving GenVec's RSV vaccine program were presented at the Keystone Symposia 2012 Meeting on Viral Immunity and Host Gene Influence.  GenVec's vaccine technology induced neutralizing antibody and significant T-cell responses with a single administration.  The immune responses were consistent with protective responses without disease potentiation, and multiple administrations increased the neutralizing antibody responses.
  • HSV Vaccine

  • GenVec conducted a successful pre-IND interaction with the U.S. Food and Drug Administration (FDA) to obtain guidance on the development plan for its vaccine against herpes simplex virus (HSV).  The outcome of the pre-IND interaction was obtaining clarification on the nonclinical, clinical, and chemistry, manufacturing, and control (CMC) requirements that need to be met in order to submit an acceptable IND.
  • Data were presented on GenVec's HSV vaccine program at the Keystone Symposia meeting on Immunological Mechanisms of Vaccination.  The Company disclosed that a single administration of its genetic vaccine was effective against HSV2 in two industry-accepted HSV disease models.
  • Mala
    '/>"/>

    SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... 2014 /PRNewswire-iReach/ -- "Spain Aesthetic Lasers and Energy ... data on the Spain Aesthetic Lasers and Energy ... of US dollars, volume (in units) and average ... Body Contouring Devices (Laser-Assisted Liposuction (LAL) Devices (Nd:YAG ... Ultrasound-Assisted Liposuction (UAL) Devices and Power Assisted Liposuction ...
    (Date:9/15/2014)... /PRNewswire-iReach/ -- On September 8, 2014, Dr. ... a Citizen Petition to Dr. Margaret Hamburg ... another Black Box Warning to Levaquin, Cipro, and ... a Black Box Warning for the following psychiatric ... or acts, loss of consciousness, delirium, depressed level ...
    (Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 ... Brussels:UCB) today announced results from several exploratory analyses of ... with low bone mineral density (BMD). Romosozumab is an ... inhibiting the protein sclerostin, thereby increasing bone formation and ... American Society for Bone and Mineral Research (ASBMR) 2014 ...
    Breaking Medicine Technology:Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15
    (Date:9/16/2014)... Triad Semiconductor, Inc. today announced that David ... former President of Linear Technology Corporation was appointed to ... technology and business expertise, and we are delighted that ... Hayden, Triad CEO and chairman. , Mr. Bell brings ... semiconductor experience to Triad's board. From 2008 to 2012, ...
    (Date:9/16/2014)... The Fertility Centers of New England is ... The collaboration will give patients access to high-quality frozen ... the Fertility Centers of New England. , Fairfax Egg ... largest selection of frozen donor eggs. Access to frozen ... , The Donor is already screened and her ...
    (Date:9/16/2014)... BamboofloorChina.com, a famous online supplier of bamboo products, has ... bamboo panels . The firm is now offering big ... high quality items. Please note that the big sale ... , According to the company’s chief executive officer, ... visit BamboofloorChina.com before September 28. BamboofloorChina.com is offering more ...
    (Date:9/15/2014)... September 16, 2014 With the variety ... is difficult to know the details on each one. ... the potential substances falling into their teen’s hands. ... marijuana itself among high school students. With varied, misleading ... and elsewhere, it can be difficult for parents to ...
    (Date:9/15/2014)... Hastings and Hastings, an experienced and established ... flat attorney fee for personal injury cases. The firm ... portion possible of their settlement or recovery as a ... personal property. In addition, Hastings and Hastings makes an ... that no fees are due unless a settlement or ...
    Breaking Medicine News(10 mins):Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Cheap Bamboo Panels Unveiled By Famous Online Supplier BamboofloorChina.com 2Health News:Teen Rehab Center CEO Releases Top 4 Facts Parents Must Know About Synthetic Marijuana 2Health News:Teen Rehab Center CEO Releases Top 4 Facts Parents Must Know About Synthetic Marijuana 3Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3
    ... is a potentially debilitating childhood disease. Early detection ... term joint damage and disability. Research has shown ... assessments in joint activity and sub-clinical disease, according ... Roentgen Ray Society,s annual meeting. The study, performed ...
    ... HealthDay Reporter , WEDNESDAY, May 4 (HealthDay News) -- ... prescribed inhaled steroids, British researchers found that the oral ... The oral medications, known as leukotriene-receptor antagonists, "have shown ... be considered for any patient, not as a last ...
    ... May 4 (HealthDay News) -- A gene essential to cardiac ... defects that cause a major proportion of childhood death from ... defects -- all malformations of the left ventricular outflow tract ... may play a role. "It is estimated that there ...
    ... LOUIS and DES MOINES, Iowa, May 4, 2011 The ... $4 million grant from the Howard G. Buffett Foundation to ... The grant will help fund the completion of the development ... Africans who depend upon sorghum as their staple diet. ...
    ... for cancer during childhood have an increased risk ... according to a new study in Gastroenterology ... Association (AGA) Institute. Compared with their siblings, cancer ... of the upper GI tract, lower GI tract ...
    ... 4 (HealthDay News) -- Vigorous exercise offers more of ... study finds. U.K. researchers compared 11 sedentary people ... assessed before, during, immediately following, and 20 minutes after ... more negative during and immediately after high-intensity exercise, compared ...
    Cached Medicine News:Health News:Sonography complements physical exam in identifying juvenile inflammatory arthritis in children 2Health News:Asthma Pills Work as Well as Inhaled Steroids: Study 2Health News:Asthma Pills Work as Well as Inhaled Steroids: Study 3Health News:New Gene Linked to Congenital Heart Defects 2Health News:Grant funds next phase in bringing healthier sorghum closer to underserved communities 2Health News:Childhood cancer survivors are at increased risk for ongoing post-therapy GI complications 2
    ... Laboratories Platelia Aspergillus EIA is a one-stage ... monoclonal antibody EBA-2 to detect circulating galactomannan ... 3 hours. , ,When used in conjunction ... is an aid in the diagnosis of ...
    ... The GreenLight PV Laser System ... the Prostate) Procedure for the ... (BPH) allows the urologist to ... a TURP with the safety ...
    ... diagnosis is generally confirmed by a positive heterophil ... however, is not indicated by the heterophil antibody ... - 20 percent of children. Detection and ... fully ascertain the stage of EBV infection. ...
    ... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
    Medicine Products: